Clinical Trial Update: CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) [Phase 2, Phase 3]

View source ↗

Summary

This update covers a Phase 2/3 clinical trial evaluating CAMPSIITE RGX-121 gene therapy for Mucopolysaccharidosis Type II (Hunter syndrome); the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• CAMPSIITE RGX-121

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Mucopolysaccharidosis Type II (MPS II) | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING